Genetic Analysis AS (“Genetic Analysis” or the “Company”) published on February 27th the Company’s Q4-report for 2025.

The following are some key points that we have chosen to highlight in connection with the report:

Strong sales momentum in constant currencies – record quarter in terms of revenue
Reagent kit sales continue to grow strongly
New product launches expected to accelerate growth going forward
Gross margin affected by import duties in the U.S.
Strong cost control and financial position

In conclusion, Genetic Analysis delivered a record quarter in Q4-25 with sales growth of approx. 3% and approx. 10% in constant currency, driven primarily by continued strong growth in high-margin, recurring GA-map® reagent kit sales, which increased 13% or 20% in constant currency. Gross margin continues to be pressured by U.S. import tariffs and currency effects, though underlying profitability remains strong. Combined with a leaner cost base and a solid cash position of NOK 24m, the Company is well positioned to scale as microbiome diagnostics gain further traction. Newly launched products, including the MHI GutHealth test, have started contributing to revenues, while the upcoming IBD Precision Dx launch in H1-26 represents an additional growth driver.

Read Analyst Group’s comment on the report here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Genetic Analysis. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.